Study Details
A Pharmacokinetic Study of Erlotinib in Cancer Patients with Advanced Solid Tumors, with Adequate and Moderately Impaired Hepatic Function
Clinicaltrials.gov ID
Astellas Study ID
OSI-774-104
EudraCT ID
2006-002363-59
Condition
Advanced/Metastatic Cancer
Phase
Phase 1
Age
18 Years - N/A N/A
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Aug 2005 - Jun 2007
Masking
None (Open Label)
Enrollment number
39
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients with Advanced Solid Tumors, with Adequate and Moderately Impaired Hepatic Function
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Pharmacokinetic Study of Erlotinib in Cancer Patients with Advanced Solid Tumors, with Adequate and Moderately Impaired Hepatic Function? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Mayo Clinic
Rochester, United States, 55905
Premiere Oncology
Santa Monica, United States, 90404
UPMC Cancer Pavilion
Pittsburgh, United States, 15232
University of Colorado Health Sciences Center
Aurora, United States, 80010
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom, G12 0YN